Phathom’s GI Pivot Pushes Revenue Momentum Toward a Profitability Path in Q1 2026

Ticker: PHAT | EPS expectations and earnings discussion loom as the company reiterates its revenue forecast and profitability timeline.

Overview

Phathom Pharmaceuticals (PHAT) released its first-quarter 2026 results alongside a business update focused on VOQUEZNA, its GI-led franchise. The company reports notable top‑line growth as it presses ahead with a pivot toward gastroenterology, backed by a disciplined cost posture. Management reiterated the full-year 2026 guidance and signaled that operating profitability is expected to arrive in the third quarter, with cash-flow positivity anticipated in 2027. For readers tracking earnings metrics, the release does not provide a GAAP EPS figure, but the narrative is thick with revenue dynamics, expense discipline, and payer access progress—staples of any EPS consensus dialogue and potential earnings surprise among analysts.

Key Financials and Usage Trends

Net revenues: $58.3 million in Q1 2026, up 104% year over year.
Operating expenses: $61.8 million for Q1; non-GAAP operating expenses of $56.2 million; net cash usage of approximately $15 million.
VOQUEZNA prescriptions: Approximately 268,000 filled in Q1; ~1.35 million total prescriptions filled as of April 17, 2026.
Insurance coverage: About 63% of Q1 prescriptions were covered by insurance; covered prescriptions rose 91% year over year.
Commercial momentum: After 2025 field realignment, the sales force is fully trained and deployed heading into Q2 2026; management highlights ongoing momentum in new-to-brand VOQUEZNA prescriptions among GI prescribers.
Share of doctors’ new prescriptions: Among Phathom’s top 3,000 GI prescribers, roughly 30% of their new-to-brand prescriptions were VOQUEZNA, versus PPIs.

Outlook and Guidance

The company maintains its FY 2026 guidance, with operating profitability anticipated in Q3 2026 and cash-flow positivity expected in 2027. Management frames this as a transition year—balancing rapid top-line growth with ongoing discipline on operating expenses and continued investments in the commercial engine and clinical pipeline. The plan hinges on VOQUEZNA’s growing payer access, solid prescription momentum, and the ability to extend market share within GI landscapes.

Management Commentary

In remarks that echo a pivot narrative rather than a one‑off beat, CEO Steven Basta stressed VOQUEZNA’s momentum and the strategic shift toward GI with a growing sales force. He framed the quarter as a validation of the company’s path to a multi-brand GI revenue trajectory—“a path to $1 billion annual revenue in gastroenterology prescriptions,” with new-to-brand prescriptions driving early momentum against traditional PPIs. CFO Sanjeev Narula emphasized disciplined cost management, noting more than 40% year‑over‑year reduction in cash operating expenses, while continuing investments in commercial capabilities and the clinical pipeline. The tone is pragmatic: growth is real, but profitability is the explicit near-term objective.

Recent Highlights and What It Signals

A few narrative threads stand out. First, VOQUEZNA’s commercial trajectory now hinges on a trained, deployed field team and improved payer dynamics. Second, the company’s cost discipline, coupled with revenue acceleration, has shifted the cash burn profile in a meaningful way, even as overall Q1 expenses remain elevated. Third, the “pivot to GI” theme—anchored by VOQUEZNA’s performance in a market dominated by established acid-suppressive therapies—suggests Phathom aims to carve out a durable, specialty GI franchise rather than chasing short-term volume.

Implications for PHAT and Sector Peers

The results underscore a broader industry pattern: smaller biotech developers with niche GI portfolios can maneuver into profitability with disciplined spend, payer strategy, and a clear path to scale. For PHAT, the key tests are the durability of VOQUEZNA demand, the pace of insurance coverage expansion, and the ability to sustain revenue growth while holding or lowering cash burn. For sector peers, the message is double-edged: strong VOQUEZNA-style execution can translate into meaningful multiple expansion if profitability materializes in Q3 2026, but the absence of a current EPS figure invites finance teams to scrutinize the earnings trajectory more closely.

Risks and Considerations

The company’s narrative depends on payer access, sustained physician adoption, and the pace of market expansion for VOQUEZNA. There is no disclosed EPS data or explicit earnings surprise in the release, so investors will watch for upcoming quarterly prints to compare against EPS consensus expectations. Any deviation from the planned profitability window or shifts in VOQUEZNA’s growth trajectory could alter the revenue forecast and, by extension, the stock’s response to the next earnings cycle.

Event Schedule

Phathom will host a conference call and webcast on April 30, 2026, at 8:00 a.m. EDT to discuss the results and the business update.